ViaCyte's hESC Diabetes Effort Examined, Critiqued in MIT Publication
The ViaCyte device -- photo San Diego U-T
The state of California has invested $55 million in a San Diego firm that last week attracted some East Coast attention for its efforts to develop a “virtual” cure involving Type 1 diabetes.
The firm is Viacyte, which is in a stage one clinical trial involving its therapy. The MIT Technology Review looked at the p…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.